Advertisement

European Child & Adolescent Psychiatry

, Volume 22, Issue 8, pp 511–518 | Cite as

Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study

  • Michael Dörks
  • Ingo Langner
  • Ulrich Dittmann
  • Antje Timmer
  • Edeltraut Garbe
Original Contribution

Abstract

The off-label use of drugs in children and adolescents is widespread. In Germany, the use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants (OADs) is not licensed for the treatment of depressive disorders in children and adolescents except for fluoxetine, which was approved in 2006. Against this background, antidepressant drug (ATD) use with a particular focus on off-label prescribing was characterised in a retrospective cohort study including cross-sectional analyses based on claims data of 2,599,685 patients up to 17 years of age. Prevalence of ATD use was 1.84 (95 % CI 1.78–1.90) per 1,000 children in 2004, 1.57 (95 % CI 1.52–1.62) in 2005 and 1.66 (95 % CI 1.61–1.72) in 2006. More than half of all children treated with ATDs (51.29 %) received only one single prescription of an ATD during the study period. Of all prescribed ATDs, 11,172 (42.09 %) were tricyclic antidepressants 9,179 (34.58 %) were SSRIs, 4,371 (16.47 %) were St John’s wort preparations and 1,821 (6.86 %) were OADs. Around half of all children and adolescents who were treated with ATDs were diagnosed with depressive disorders (56.30 %). Overall, 13,035 (49.11 %) of all ATDs were prescribed off-label. Off-label use by age (40.18 %) was found to be more common than off-label use by indication (16.63 %) with 7.70 % of off-label use occurring in both categories. Specialist treatment by hospital-based physicians increased the risk (odds ratio: 2.26, 95 % CI 2.05–2.48) of receiving an off-label prescription compared to treatment by general practitioners. In summary, off-label use of ATDs in children and adolescents was substantial in Germany.

Keywords

Off-label use Antidepressants Prevalence Children Pharmacoepidemiology German Pharmacoepidemiological Research Database 

Notes

Acknowledgments

The authors are grateful to all statutory health insurances which provided data for this study, namely the AOK Bremen/Bremerhaven, the Techniker Krankenkasse (TK), the DAK-Gesundheit and the hkk.

Conflict of interest

This project was financed by internal funds of the BIPS—Institute for Epidemiology and Prevention Research. M. Dörks is involved in studies unrelated to this project funded by Celgene GmbH and Sanofi-Aventis Deutschland GmbH. A. Timmer is involved in studies unrelated to this project funded by Novartis Pharma GmbH and Sanofi-Aventis Deutschland GmbH and received funding from Abbott GmbH and Co. KG, Ferring Arzneimittel GmbH and Takeda Pharma GmbH. E. Garbe is running a department that occasionally performs studies for pharmaceutical industries with the full freedom to publish. The companies include Mundipharma, Bayer-Schering, Stada, Sanofi-Aventis, Sanofi-Pasteur, Novartis, Celgene and GSK. She has been consultant to Bayer-Schering, Nycomed, Teva and Novartis in the past. The present work is unrelated to the above grants and relationships.

Ethics and consent

The use of statutory health insurance (SHI) data for scientific research is regulated by the Code of Social Law in Germany (SGB X). All involved SHIs, the Federal Ministry of Health (for federal SHI data) and the provincial health authority (for regional SHI data) approved the use of the data for this study. Informed consent of the involved insurants was not required by law since this study was based on pseudonymous data.

Reference

  1. 1.
    EMA: The European paediatric initiative: History of the Paediatric Regulation; 2007. Doc. Ref: EMEA/17967/04 Rev 1. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003693.pdf. Accessed: 25.05.2012
  2. 2.
    Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC (2006) Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry 67(6):972–982PubMedCrossRefGoogle Scholar
  3. 3.
    Fegert JM, Kolch M, Zito JM, Glaeske G, Janhsen K (2006) Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16:197–206PubMedCrossRefGoogle Scholar
  4. 4.
    Clavenna A, Bonati M (2012) Antidepressant prescriptions in paediatric outpatients in Europe. Paediatr Perinat Drug Ther 2007 8(3):103–108CrossRefGoogle Scholar
  5. 5.
    Bucheler R, Meisner C, Kalchthaler B, Mohr H, Schroder H, Morike K, Schwoerer P, Schwab M, Gleiter CH (2002) “Off-label” prescribing of drugs in the ambulatory care of children and adolescents. Dtsch Med Wochenschr 127:2551–2557PubMedCrossRefGoogle Scholar
  6. 6.
    Hoffmann F, Glaeske G, Petermann F, Bachmann CJ (2012) Outpatient treatment in German adolescents with depression: an analysis of nationwide health insurance data. Pharmacoepidemiol Drug Saf 21(9):972–979. doi: 10.1002/pds.3295. Epub 2012 May 28PubMedCrossRefGoogle Scholar
  7. 7.
    Pigeot I, Ahrens W (2008) Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 17:215–223PubMedCrossRefGoogle Scholar
  8. 8.
    EMA: Note For Guidance On Clinical Investigation Of Medicinal Products In The Paediatric Population; 2001. CPMP/ICH/2711/99. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf. Accessed: 25.05.2012
  9. 9.
    Daly LE (1998) Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 147:783–790PubMedCrossRefGoogle Scholar
  10. 10.
    Volkers AC, Heerdink ER, van Dijk L (2007) Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001–2005). Pharmacoepidemiol Drug Saf 16:1054–1062PubMedCrossRefGoogle Scholar
  11. 11.
    Zito JM, Tobi H, de Jong-van den Berg LT, Fegert JM, Safer DJ, Janhsen K, Hansen DG, Gardner JF, Glaeske G (2006) Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 15:793–798PubMedCrossRefGoogle Scholar
  12. 12.
    National Institute for Health and Clinical Excellence: depression in children and young people; identification and management in primary, community and secondary care 2005. http://www.nice.org.uk/nicemedia/pdf/CG028NICEguideline.pdf. Accessed: 25.05.2012
  13. 13.
    American Academy of Child and Adolescent Psychiatry (2007) Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46(11):1503–1526CrossRefGoogle Scholar
  14. 14.
    Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J, Gleiter CH (2007) Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf 16:1153–1160PubMedCrossRefGoogle Scholar
  15. 15.
    Murray ML, de Vries CS, Wong IC (2004) A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 89:1098–1102PubMedCrossRefGoogle Scholar
  16. 16.
    Dt.Ges.f. Kinder- und Jugendpsychiatrie und Psychotherapie u.a. (Hrsg.): Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzte Verlag, 3. überarbeitete Auflage 2007—ISBN: 978-3-7691-0492-9, S. 57–71Google Scholar
  17. 17.
    van Esso D, Del Torso S, Hadjipanayis A, Biver A, Jaeger-Roman E, Wettergren B, Nicholson A (2010) Paediatric primary care in Europe: variation between countries. Arch Dis Child 95:791–795PubMedCrossRefGoogle Scholar
  18. 18.
    Kölch M, Prestel A, Singer H, Keller F, Fegert JM, Schlack R, Hoelling H, Knopf H (2009) Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 19:765–770CrossRefGoogle Scholar
  19. 19.
    Butler RJ, Heron J (2008) The prevalence of infrequent bedwetting and nocturnal enuresis in childhood. A large British cohort. Scand J Urol Nephrol 42:257–264PubMedCrossRefGoogle Scholar
  20. 20.
    European Medicines Agency Press Release: European Medicines Agency finalises review of antidepressants in children and adolescents. 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SSRI_31/WC500013082.pdf. Accessed: 06.11.2012
  21. 21.
    Bundesinstitut für Arzneimittel und Medizinprodukte: Antidepressiva: Wissenschaftliche Neubewertung der SSRI/SNRI abgeschlossen—Neue Warnhinweise auf suizidales Verhalten bei Kindern und Jugendlichen. 2005. http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/2005/RI-antidepressiva-neubewertung.html. Accessed: 06.11.2012
  22. 22.
    Bundesinstitut für Arzneimittel und Medizinprodukte BfArM. Zusätzliche Warnhinweise zum suizidalen Risiko bei Kindern und Jugendlichen für Ihre Arzneimittel aus der Gruppe der tricyclischen Antidepressiva (TCA). 2005. http://www.bfarm.de/SharedDocs/1_Downloads/DE/Pharmakovigilanz/am-sicher-akt/TCA-Schreiben050826.pdf?__blob=publicationFile. Accessed: 06.11.2012
  23. 23.
    Schirm E, Tobi H, de Jong-van den Berg LT (2003) Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 111:291–295PubMedCrossRefGoogle Scholar
  24. 24.
    Dittmann RW, Linden M, Osterheider M, Schaaf B, Ohnmacht U, Weber HJ (1997) Antidepressant drug use: differences between psychiatrists and general practitioners. Results from a drug utilization observation study with fluoxetine. Pharmacopsychiatry 30:28–34PubMedCrossRefGoogle Scholar
  25. 25.
    Lee E, Teschemaker AR, Johann-Liang R, Bazemore G, Yoon M, Shim KS, Daniel M, Pittman J, Wutoh AK (2012) Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol Drug Saf 21(2):137–144. doi: 10.1002/pds.2145. Epub 2011 Apr 28PubMedCrossRefGoogle Scholar
  26. 26.
    Schink T, Garbe E (2010) Representativity of dispensations of non-steroidal anti-inflammatory drugs (NSAIDs) in the German Pharmacoepidemiological Research Database. 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) 19–22 August 2010, Brighton, England. Abstract published in: Pharmacoepidemiology and drug safety 19(Suppl 1):695Google Scholar
  27. 27.
    Schink T, Garbe E (2010) Assessment of the representativity of in-patient hospital diagnoses in the German Pharmacoepidemiological Research Database. 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), 19–22 August 2010, Brighton, England. Abstract published in: Pharmacoepidemiology and Drug Safety. 19(Suppl 1):420Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Michael Dörks
    • 1
  • Ingo Langner
    • 1
  • Ulrich Dittmann
    • 1
  • Antje Timmer
    • 1
  • Edeltraut Garbe
    • 1
  1. 1.BIPS—Institute for Epidemiology and Prevention ResearchBremenGermany

Personalised recommendations